Omics analyses of a somaticTrp53R245W/+breast cancer model identify cooperating driver events activating PI3K/AKT/mTOR signaling

Authors:

Abstract
Alterations of the tumor suppressorTP53, one of the most common events in cancer, alone are insufficient for tumor development but serve as drivers of transformation. We sought to identify cooperating events through genomic analyses of a somaticTrp53R245Wmouse model (equivalent to theTP53R248Whot spot mutation in human cancers) that recapitulates metastatic breast–cancer development. We identified cooperating lesions similar to those found in human breast cancers. Moreover, we identified activation of the Pi3k/Akt/mTOR pathway in most tumors via mutations inPten,Erbb2,Kras, and/or a recurrentPip5k1cmutation that stabilizes the Pip5k1c protein and activates Pi3k/Akt/mTOR signaling. AnotherPIP5K1Cfamily member,PIP5K1A, is coamplified withPI4KBin 18% of human breast cancer patients; both encode kinases that are responsible for production of the PI3K substrate, phosphatidylinositol 4,5-bisphosphate. Thus, theTP53R248Wmutation and PI3K/AKT/mTOR signaling are major cooperative events driving breast-cancer development. Additionally, a combination of two US Food and Drug Administration (FDA)-approved drugs, tigecycline and metformin, which target oxidative phosphorylation downstream of PI3K signaling, inhibited tumor cell growth and may be repurposed for breast-cancer treatment. These findings advance our understanding of how mutant p53 drives breast-tumor development and pinpoint the importance of PI3K/AKT/mTOR signaling, expanding combination therapies for breast-cancer treatment.
Funding Information
  • Cancer Prevention and Research Institute of Texas (RP180313)
  • HHS | NIH | National Cancer Institute (CA82577)